\
&
Contact us
\
&
Contact us
This was 2 weeks ago
LocationOnline
ProgrammesThis online information day aims to inform (potential) applicants about the 2026 topics included in the Cluster 2 'Culture, Creativity and Inclusive Society' work programme 2026-2027.
Cluster 2: Culture, Creativity and Inclusive Society aims to meet EU goals and priorities on enhancing democratic governance and citizens participation, on the safeguarding and promotion of cultural heritage, and to respond to and shape multifaceted social, economic, technological and cultural transformations.
More information on this info day can be found here.
In order to dedicate more time to the Q&A part, presentations of the 2026 call topics will be uploaded on the website and should be watched prior to the info day. You can send your questions in advance via Sli.do by using #CL2Infoday, so that the questions can be answered fully and in priority during the live event.
In addition to the info day, a brokerage event for Cluster 2 is planned on 1-2 June 2026 in Paris, France. This on-site only event will include an information session, pitch presentations of consortia in preparation, as well as the opportunity for bilateral meetings with partners interested in the same topics for the 2026 calls. More information will be available in soon. The Net4Society matchmaking community platform remains always open.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
